Week’s news headlines – may 15th 2015

#Trademarks?: Hashtags as trademarks

Hashtags have become ubiquitous in social media, but their status as intellectual property—particularly as trademarks—is still developing. First adopted by Twitter users to link user posts, hashtags are character strings preceded by the “#” symbol that generate a link to all other posts containing the same tag. Today, in addition to providing the search-related functionality for which they were first developed, hashtags provide businesses new ways to  engage with consumers. Hashtag marketing campaigns by businesses generate brand awareness by encouraging social media users to post with the campaign tag and, in return, offer users discounts, prizes or even a chance to become a model.

Saiba mais em: http://www.lexology.com/librar

 

 

 

Feathers fly in trademark battle

It’s a classic David vs Goliath battle. US multinational Indian ­Motorcycles is throwing its sizeable weight at a 45-year-old Sydney small business, Chieftain Canopies, because the family operation owns the trademark that it wants for one of its products.

Saiba mais em: http://www.theaustralian.com.a

 

 

 (Illegal) Drugs and Trademarks

After thinking more about the recent decision by the U.S. Patent and Trademark Office to (at least initially) refuse federal registration status to the mark SLANTS used by a band of performers of primarily Asian descent, (see May 6, 2915 blog post “Disparagement, Political Correctness and the First Amendment”), I thought that, just for fun, I would check whether the relatively recent legalization of marijuana in a couple of states has led to rash of MARIJUANA mark filings.  Yup.

Saiba mais em: http://www.trademarkologist.com/2015/05/

Read more

New rules, new oportunities…

2015 began with the publication of new rules in healthcare area that will contribute to the emergence of opportunities for industries in the sector and in the country as a whole.

 

The enactment of Law No. 13,097, on January 19th, 2015, has brought more flexibility to ANVISA’s actions, so that these actions are directed to situations of greater impact on society, ultimately allowing the development of the healthcare sector, as for example, in cases of clinical trials. Another advantage brought by this new law to the healthcare industries is related to the validity term of healthcare products’ registration under ANVISA’s surveillance. In fact, the referred law makes it possible to extend the validity term from 5 to 10 years, considering the product’s nature and the sanitary risks involved in its use. Furthermore, Law No. 13,097, establishes that the industries in the sector are exempted from payment of renewal fees.

 

Finally, for the purposes of supervision and monitoring of products subject to Health Surveillance system, the referred law also foresees the use of sanitary inspection reports by agencies or international institutions accredited by ANVISA.

 

Furthermore, ANVISA published Resolution RDC No. 09, on February 20, 2015, establishing new rules for the development of clinical trial of medicinal product in Brazil. This resolution defines the maximum period of 30 days for ANVISA to assess the Clinical Development of the Medicinal Product Report (DDCM) prepared by the company that either owns the drug or by the clinical agency doing the testing. Where ANVISA does not manifest in time, the clinical trial can be conducted, as long as it is approved on the ethical aspects of the research. However, regarding experimental drugs, in order to be allowed to proceed to Phase I and Phase II, as well for clinical development of biological products, the previous approval of ANVISA is still necessary. Clinical researches in the examination phase III, to be held simultaneously in different countries, will also benefit from this new rule.

 

The new rule also provides a type of approval that concentrates all phases of clinical studies into one single analysis, in order to harmonize national legislation on the subject with other international regulatory bodies.

language: EN-US’>

 

The new rule also provides a type of approval that concentrates all phases of clinical studies into one single analysis, in order to harmonize national legislation on the subject with other international regulatory bodies.

 

 

For more details please feel free to contact us:

diblasi@diblasi.com.br

Read more

Our Offices

developed by
Pedro.am

convite_BIO_2015 popup

×